Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-201 in Advanced HER2+ Solid Tumors
NCT06341647Phase 1Withdrawn
- Sponsor
- GC Cell
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, CAR-NK Cells
01
Overview
Phase 1, open-label trial of AB-201 in breast cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by GC Cell. Primary endpoints: Incidence, severity, seriousness, and dose relationship of Adverse Events up to 18 months and Determination of Recommended Phase 2 Dose up to 18 months. Planned start Oct 2024; status: withdrawn.
02
Drugs
AB-201
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06341647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341647.